Phd thesis defense Anna Oja: Functionality of CD4+ TRM cellsNews
On June 18, Sanquin researcher Anna Oja will defend her PhD thesis at the University of Amsterdam. Her research sheds light on the functionality of CD4+ TRM, which could be targeted in novel vaccine strategies and anti-cancer immunotherapies.
Current vaccine strategies and cancer immunotherapies rely heavily on the induction of cytotoxic CD8+ T cells. CD4+ T cell help is required for optimal CD8+ T cell responses. Whether CD4+ T cells have a similar role in human tissues and cancer requires further investigation.
In this thesis, we focused on the characterization of less conventional functions of human CD4+ T cells in different tissue compartments and cancer. Transcription factor Hobit identifies cytotoxic CD4+ T cells that arise during primary hCMV infection.
We further defined the core signature of human lung CD4+ TRM, which display properties of CD8+ TRM and have a fast and polyfunctional recall response. Lung CD4+ TRM localize in heterogeneous patterns and consist of distinct subsets of TH1 and TH17 TRM, recognizing numerous pathogens.
NSCLC tumors also contain polyfunctional pathogen-specific CD4+ TILs with a residency phenotype and PD-1 expression distinguishes functionally distinct subsets. The abundance of CXCL13+CD4+ TILs with a residency phenotype, significantly correlates with survival and frequencies of CD8+ TIL subsets shown to be enriched for tumor-specificity. This suggests that CXCL13+CD4+ TILs are important in anti-tumor immunity and reflect a patient’s ability to form an anti-tumor response.
CD4+ TRM are also protective against coronaviruses. SARS-CoV-2 elicits a strong TH1 T cell response. COVID-19 ICU patients develop high antibody titers, but an impaired CD4+ T cell response. Furthermore, BALF of these patients contain T cells resembling circulating cells rather than TRM, suggestive of vascular leakage, altogether indicating misbalanced cellular and humoral responses in patients unable to control SARS-CoV-2 infection. Taken together, our findings shed light on the functionality of CD4+ TRM, which could be targeted in novel vaccine strategies and anti-cancer immunotherapies.
Prof RAW van Lier MD PhD
P Hombrink PhD
MA Nolte PhD
University of Amsterdam, Agnietenkapel (invitation only) and online.